Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
McKesson
Mallinckrodt
Baxter
Colorcon

Last Updated: January 22, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR AZD-5423

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Clinical Trials for AZD-5423

Trial ID Title Status Sponsor Phase Summary
NCT00245063 AZD2171 in Treating Patients With Recurrent Small Cell Lung Cancer Completed National Cancer Institute (NCI) Phase 2 This phase II trial is studying how well AZD2171 works in treating patients with recurrent small cell lung cancer. AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
NCT00568776 ELND005 in Patients With Mild to Moderate Alzheimer's Disease Completed Transition Therapeutics Phase 2 The purpose of this study is to evaluate the dose-related safety and efficacy of multiple oral dosages of ELND005 as treatment for Alzheimer's disease (AD).
NCT00568776 ELND005 in Patients With Mild to Moderate Alzheimer's Disease Completed Transition Therapeutics Ireland Limited Phase 2 The purpose of this study is to evaluate the dose-related safety and efficacy of multiple oral dosages of ELND005 as treatment for Alzheimer's disease (AD).
NCT00686998 Phase IIA Study in Patients With Schizophrenia Completed AstraZeneca Phase 2 This study is designed to assess the effects of AZD 2624 in patients with schizophrenia
NCT00690404 AZD 2066 Single Dose Formulation and Food Effect Study in Healthy Volunteers Completed AstraZeneca Phase 1 A open label two way crossover formulation and food effect study in healthy volunteers to assess the pharmacokinetics of a single dose of AZD2066 new oral solid formulation and an oral solution
NCT00755378 AZD8529 Single Ascending Dose Study Completed AstraZeneca Phase 1 This is a study to evaluate safety, tolerability, PK and PD effects of orally administered AZD8529 after single ascending doses
NCT00758459 Safety/Tolerability Study With AZD1236 in Chronic Obstructive Pulmonary Disease (COPD) Patients Completed AstraZeneca Phase 2 The primary aim of this study is to investigate the tolerability and safety of AZD 1236 compared with placebo ("inactive substance") in COPD patients by assessment of Adverse Events, vital signs and laboratory safety assessments.
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for AZD-5423

Condition Name

Condition Name for
Intervention Trials
Healthy 5
Recurrent Fallopian Tube Carcinoma 2
Recurrent Primary Peritoneal Carcinoma 2
Chronic Obstructive Pulmonary Disease 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for
Intervention Trials
Adenocarcinoma 3
Ovarian Neoplasms 3
Small Cell Lung Carcinoma 3
Lung Neoplasms 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for AZD-5423

Trials by Country

Trials by Country for
Location Trials
United States 73
Canada 12
United Kingdom 6
Korea, Republic of 4
Japan 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for
Location Trials
Pennsylvania 7
California 5
Texas 4
New York 4
Indiana 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for AZD-5423

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase Trials
Phase 2 15
Phase 1 14
N/A 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase Trials
Completed 18
Recruiting 7
Not yet recruiting 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for AZD-5423

Sponsor Name

Sponsor Name for
Sponsor Trials
AstraZeneca 19
National Cancer Institute (NCI) 5
Samsung Medical Center 4
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for
Sponsor Trials
Industry 23
Other 10
NIH 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Merck
Dow
McKesson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.